Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Agent for overcoming immunosuppression and use thereof
US11213538B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11213538-B2 |
| Application number | US-201716073871-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 15, 2017 |
| Priority date | Feb 16, 2016 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for overcoming immunosuppression by regulatory T cells, the method comprising administering to a patient epirubicin or a salt thereof, in a dose range of 0.1 mg/kg to 0.25 mg/kg, wherein the patient has a solid cancer. 2. The method of claim 1 , further comprising another anticancer therapy. 3. The method of claim 2 , wherein the another anticancer therapy is a cancer chemotherapy or a cancer immunotherapy. 4. The method of claim 3 , wherein the another anticancer therapy is a cancer immunotherapy selected from the group consisting of an immune checkpoint blockade therapy, a cancer vaccine therapy, and a T cell transfer therapy.
Assignees
Inventors
Classifications
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title
Immunomodulators · CPC title
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11213538B2 cover?
- To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
- Who is the assignee on this patent?
- General Incorporated Ass Pharma Valley Project Supporting Organization, Yakult Honsha Kk
- What technology area does this patent fall under?
- Primary CPC classification A61K31/704. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).